2000 : Ascend is organized and begins its work developing products.
2007 : Ascend receives its first independent approval for the product Benzonatate.
2008 : Ascend launches its own label into the market.
2010 : Ascend meets and partners with Alkem.
2012 : Ascend sells outstanding shares to Alkem and becomes US subsidiary.
2014 : Alkem/Ascend receives first exclusive generic approval from FDA on Mycophenolate Suspension.
2015 : Alkem/Ascend acquires Norac, a DEA API manufacturer in Azusa , CA.
Alkem/Ascend acquires Long Pharma in Fenton Mo. Long is the prior Fleming facility for Finished Dose Formulation work.